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Background: A care pathway is defined as patient-focused global care that addresses temporal (effective and
coordinated management throughout the illness) and spatial issues (treatment is provided near the health territory
in or around the patient’s home). Heterogeneity of the care pathways in breast cancer (BC) is presumed but not
well evaluated. The OPTISOINS01 study aims to assess every aspect of the care pathway for early BC patients using
a temporal and spatial scope.
Methods/Design: An observational, prospective, multicenter study in a regional health territory (Ile-de-France,
France) in different types of structures: university or local hospitals and comprehensive cancer centers. We will
include and follow during 1 year 1,000 patients. The study consists of 3 work-packages:
- Cost of pathway
The aim of this WP is to calculate the overall costs of the early BC pathway at 1 year from different perspectives
(society, health insurance and patient) using a cost-of-illness analysis. Using a bottom-up method, we will assess
direct costs, including medical direct costs and nonmedical direct costs (transportation, home modifications, home
care services, and social services), and indirect costs (loss of production).
- Patient satisfaction and work reintegration
Three questionnaires will assess the patients’ satisfaction and possible return to work: the occupational questionnaire
for employed women; the questionnaire on the need for supportive care, SCNS-SF34 (‘breast cancer’ module,
SCNS-BR8); and the OUTPASSAT-35 questionnaire.
- Quality, coordination and access to innovation
Quality will be evaluated based on visits and treatment within a set period, whether the setting offers a
multidisciplinary consultative framework, the management by nurse coordinators, the use of a personalized
care plan, the provision of information via documents about treatments and the provision of supportive care.
The coordination between structures and caregivers will be evaluated at several levels. Day surgery, home
hospitalization and one-stop breast clinic visits will be recorded to assess the patient’s access to innovation.
Discussion: The assessment of care pathways encourages the implementation of new payment models. Our
approach could help health care professionals and policymakers to establish other cost-of-illness studies and plan
the allocation of resources on a patient basis rather than a visit basis.
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Table 1 Patient selection
Inclusion criteria
- Histologically confirmed, previously untreated, operable
breast cancer
- Residence in the Yvelines, Hauts-de-Seine or Val d’Oise
departments
- Age ≥18 years
- Sex: female
Exclusion criteria
- Previous history of breast cancer
- Metastatic, locally advanced, or inflammatory breast cancer,
as defined by the AJCC (7th Edition).
- Unstable over the following 12 months
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Health care systems have evolved into care pathway
models in response to chronic diseases and the expendi-
tures related to them. Disease management tends to be
multidisciplinary and transversal, reducing the historic
place of the hospital in favor of other long-term sup-
ports. The shortcomings of health care for chronic dis-
ease are shared issues for a number of countries. Cancer
has become a chronic disease as a result of improved
treatment. Breast cancer (BC) is a good example of a
chronic cancer. Incidence, therapeutics, practices and
costs of BC can vary substantially in a given area. There
are 1.15 million incident cases of breast cancer per year
worldwide [1]. The disease results in high costs in terms
of care, out-of-pocket expenses and losses of productiv-
ity; the cost of breast cancer was 126 billion € in 2009 in
Europe, corresponding to 12 % of all cancer-related costs
[2]. Moreover, the heterogeneity of BC-related care path-
ways and structures at the regional level are presumed
but not well evaluated.
Some international health policies aim to take a more
global view of chronic disease. In France, a 2004 law
named the referring physician as the organizer of the
patient care pathway [3]. In 2009, the HPST law
assigned a central role to the regional health agency
(ARS) to improve the continuity of care in a given
health territory in France [4]. A care pathway is de-
fined by the ARS as patient-focused global care that
takes a territorial approach. The concept includes
education, prevention, diagnosis, treatment, rehabilita-
tion, surveillance and social care. The care pathway
addresses temporal (effective and coordinated man-
agement throughout the illness) and spatial issues
treatment provided in or near the patient’s home
health territory). The aim is to provide well-defined
practices at well-defined times and places. Care path-
ways are also presumed to favor equity by facilitating
access to care and to improve efficiency by reducing
the inappropriate use of health resources.
National initiatives and incentives have enhanced
planned care. The chronic care model [5, 6], the use of
patient-centered medical homes (PCMH) or the facili-
tation of practice in primary care are being actively
promoted and tested in the United States along with
bundled payment for some surgical treatments [7]. How-
ever, all of these processes focus on small portions of the
care pathway. Multidimensional evaluations of the BC
pathway have not yet been described.
Our study, OPTISOINS01, aims to assess every aspect
of the care pathway for early BC patients from a chrono-
logical and spatial scope. It will describe the stages of
the care pathway, including innovative organization. In
this paper, we will describe the objectives and the design
of the study.Methods
OPTISOINS01 is an observational, prospective, multicen-
ter study conducted with patients from a determined re-
gional health territory. This study was approved by the
French National ethics committee (CCTIRS Authorization
n°14.602 and CNIL DR-2014-167) and covers research at
all participating hospitals.Setting and population
The three departments of interest in this study (Hauts-
de-Seine, Yvelines, and Val d’Oise) cover 35 % of the
population of the Ile-de-France region (total population:
11.9 million). With 2.17 million women living in this
area, 61 % of whom are older than 45 years, the inci-
dence and mortality of BC in this area are higher than
the national rates. This territory was chosen for its
heterogeneity in terms of the health care services
provided and for its variation in professional densities
and facilities, which is linked to the disparate urba-
nization and population incomes throughout the territory.
Eight nonprofit hospitals participate in the study: three
university hospitals (Antoine Béclère hospital, Clamart,
France; Bichat-Beaujon hospital, Clichy and Paris, France;
Louis Mourier hospital, Colombes, France), four local
hospitals (André Mignot, Versailles, France; René Dubos,
Pontoise, France; Poissy-St Germain hospital, Poissy,
France; Victor Dupuy hospital, Argenteuil, France) and
one comprehensive cancer center (Curie Institute, Paris
and St Cloud, France). These are the hospitals that treat
the most BC patients in the Yvelines, Hauts-de-Seine and
Val d’Oise departments. Each hospital will include
between 30 and 450 patients over 4–6-month period,
depending on the yearly number of BC patients treated.
A total of 1,000 patients will be included; approximately
150 will undergo outpatient surgery, and 200 will have
home hospitalizations. The inclusion and exclusion
criteria are presented in Table 1.
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Patients will be approached for the study during their
surgery programming visit. The patients will be followed
for 1 year, as described in Fig. 1.
Objectives and endpoints
This study aims to identify the main care pathway after 1
year of early BC and to evaluate costs from different per-
spectives. The secondary objectives are to assess patient sat-
isfaction, needs for supportive care, and work reintegration
and to evaluate interactions between health care providers
in and out of the hospital. In light of these objectives, the
study consists of three work packages (WPs).
WP1: cost of pathway
The aim of this WP is to calculate the overall costs of
the early BC pathway at 1 year from different perspec-
tives (society, health insurance and patient) using a cost-
of-illness analysis. Using a bottom-up method, we will
assess direct costs, including medical direct costs and
nonmedical direct costs (transportation, home modifica-
tions, home care services, and social services), and indir-
ect costs (loss of productivity). Productivity losses will
be measured in terms of lost wages using a human
capital approach (HCA). From a societal perspective, the
HCA estimates an individual’s contribution to society byFig. 1 OPTISOIN study designapplying labor force earnings as a measure of productiv-
ity. We will evaluate the out-of-pocket health expenses
for BC. These include the costs associated with the use
of health care services, alternative therapies, dietary sup-
plements, specific cosmetic products, capillary pros-
thesis, clothes, domestic help and travel expenses. The
protocol includes different data sources. Each patient
will use a logbook to provide information about her
socio-demographic status, her type of health insurance,
her outpatient consumptions, her out-of-pocket ex-
penses and her modes of work reintegration. The patient
will update the logbook monthly from the post-surgical
visit until the 1-year follow-up.
WP2: patient satisfaction and work reintegration
Three questionnaires will assess the patients’ satisfaction
and possible return to work.
 The occupational questionnaire for employed
women includes the following items: dates of work
and absence from work during treatments, work
arrangements, on-shift status (e.g., the recognition
of disability at work, applications for disability
allowance, retirement, layoff ) and the perceived
quality of reintegration (e.g., relationships with
colleagues and line management).
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its ‘breast cancer’ module, SCNS-BR8 [9] includes
six care need subscales: “Physical and Daily Living”,
“Psychological”, “Health System and Information”,
“Patient Care and Support”, “Sexuality” and “Breast
Cancer Specific Needs”. Response scores are
standardized on a scale ranging from 0 to 100 with
higher scores indicating higher needs. Adequate
internal consistency (Cronbach’s α) estimates ranged
from 0.80–0.93 in a French validation [10].
 The OUTPASSAT-35 questionnaire [11] is adapted
from the EORTC IN-PATSAT32 questionnaire
[12] and has 35 items. The first two parts address
physician and nurse care in terms of the professionals’
technical skills, relational quality, information
provided and availability. The third part broaches
service and organization in terms of information
sharing among care providers, the identification of
a referring physician, information provided by
other staff members, wait times, and the physical
environment of the hospital. Patients respond to
the items using a 5-point scale. Summing the patient’s
responses to the relevant items yields scores for each
field and a total score that can be standardized on a
scale from 0 to 100, with higher scores indicating
higher patient satisfaction (Cronbach’s α ranging
from 0.72 to 0.93).
WP3: quality, coordination and access to innovation
Quality will be evaluated based on the visits and treat-
ment during a given period, whether the setting applies
a multidisciplinary consultative framework, the manage-
ment by nurse coordinators, the use of a personalized
care plan, and the delivery of information documents
related to treatments and supportive care.
Coordination and collaboration among structures and
caregivers will be evaluated on several levels. The hos-
pital care provider questionnaire addresses the practices
of physicians who are in contact with the patient and
the sharing of tools with outpatient caregivers. The re-
ferring physician questionnaire describes the role of the
referring physician and his interaction with hospital
caregivers. The center questionnaire addresses the hos-
pital’s organization and activity and their labor and logis-
tics expenses. An electronic case report form collects
medical data and inpatient consumptions.
Several levels of collaboration will be assessed: the
organization among different types of professionals
within the same hospital, the collaboration among struc-
tures, and the individual collaborations among physi-
cians within and outside the hospital.
Outpatient surgery, home hospitalization and one-stop
breast clinic visits will be recorded to assess access to
innovation.Statistical analysis
The statistical analysis will be conducted in three steps.
First, a descriptive analysis will be conducted on the
population studied and on the care pathways.
Second, homogeneous groups of patients will be estab-
lished based on the patients’ individual medical informa-
tion, such as age, surgical management procedures, and
adjuvant therapy (radiotherapy and chemotherapy). For
a given homogeneous group of patients, care pathways
and endpoints will be compared. The endpoints are the
costs of care pathways, patient satisfaction, work reinte-
gration, readmissions and time lapses between care
stages. The variability of these endpoints will be studied
in light of the patients’ socio-demographic characteristics
and geographical situation and the structure of care. The
third part of the analysis will consist of a descriptive
approach, regardless of the group to which the patient
belongs. A multiple correspondence analysis will be con-
ducted with care resource use and socio-demographic
and medical characteristics as active variables. The vari-
ables that constitute the endpoints will be projected onto
a space defined by appropriate axes.
Discussion
In the United States, the diversity of care pathways is
limited by managed care plans. Coverage restrictions en-
courage patients to follow a certain care pathway within
a network of health care providers that contract with in-
surers. Historically, the French health care system is
characterized by the founding principle of liberty: liberty
both for physicians to practice and for patients to use
health care services. Currently, to control growing health
care expenses, a number of questions and considerable
debate has focused on the organization of care pathways.
However, it appears that there is no general or unique
scope for these pathways and no established monetary
valuation of the cost pathways for any disease. The
French National Cancer Institute has specifically called
for proposals on economic assessments of care pathways
since 2013. The OPTISOINS01 study was the only pro-
ject that was positively perceived, and it was selected for
a national grant in 2013.
The spatial and temporal scope of the care pathway still
needs to be defined
To our knowledge, no term that describes the whole
care process has been found in the literature. Authors
often use the term “care pathway” without defining it
specifically [13] or confuse the concept and the tool
designed for its practical application (e.g., the European
pathway association). The term “care pathway” is
commonly used as a synonym for “clinical pathway”,
“critical pathway”, “integrated care pathway” or “care
map” to name the tool used to standardize care for a
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acts to be performed by a single multidisciplinary team
to meet established guidelines at a local level.
We chose to use the term “care pathway” to refer to
the concept behind this quality improvement tool. As
we use it, “care pathway” indicates the effective succes-
sion of care, structures and providers throughout the
illness for each patient. The care pathways in our study
are not planned but are observed as they happen. The
succession of actors from several structures over a given
period of time implies the temporal and spatial aspects
of the care pathway. Because the notion of care pathway
is global and includes the entire care process, the time
frame and the spatial frame must be defined.
Several empirical studies have been published on the
BC clinical pathway. Studies often compare patients’
situations before and after the clinical pathway imple-
mentation using selected indicators in the care process
[14], and they sometimes compare costs [15, 16].
Some studies evaluate the 1-year costs of BC but do
not give details about the care services that compose the
care pathway [17] or assess only hospital-specific cost
items, excluding the social and ambulatory care sectors
[17, 18]. A model of the care pathway for new, non-
metastatic BC has been proposed; it describes the tem-
poral sequence of hospital care, but its costs were not
assessed [19]. One published study evaluating BC pathways
has been found in the literature. The authors assessed the
1-year care pathway of patients who underwent breast
cancer surgery in 2009 in France. They proposed a
method for grouping care pathways over a sequence of
hospitalizations using claim data [18]. The pathway
studied included only the hospital portion of the BC care
at 1 year and did not refer to a specific health territory.
The assessment of care pathways encourages the
implementation of new payment models
One major challenge associated with the optimization of
a cancer care pathway is the implementation of new pro-
spective payment methods, such as patient-based bun-
dled payments.
Hospitals are usually funded by a prospective payment
system based on diagnosis-related groups (DRGs). Pa-
tient assignments to DRGs are based on their primary
diagnosis. This classification system was adapted from
the US Healthcare Financing Group classification. The
DRGs’ prices (tariffs) are established annually at a na-
tional level based on average costs. The financing of
health care services implies the involvement of an indi-
vidual producer, such as the hospital, the laboratory, the
self-employed physician or the radiology center for ex-
ample. The prospective payment system encourages the
segmentation and multiplication of examinations or
visits.New payment models aim to encourage the efficiency of
care pathway. In the United States, bundled payment, also
known as episode-based payment, has been proposed as a
strategy for reducing health care costs during health care
reform debates, especially during the Obama administra-
tion. This type of payment is currently being implemented
for surgery cases [7]. It replaces payments for each pro-
vider during a health care episode. This payment approach
offers a single or package payment and implies that initial
negotiation among providers and contract with the payers
(health insurance) has occurred. Using an overall ap-
proach, the payers assess the resources consumed during
each care episode and valorize them according to the aver-
age cost linked to best practices. This method takes into
account the dispersion of patient outliers, introducing
variability into the average management pathway and lim-
iting losses through “stop loss” and other contracts that
limit the financial losses for each professional. Our study
will provide confidence intervals for bundled payments ac-
cording to practice settings and regional parameters.
Bundled payment is expected to increase the efficiency
and quality of health care because under that model, the
financial risks are held by the health care providers. It
aims to promote sharing and coordination among health
professionals and to encourage a patient-focused care
pathway approach in accordance with clinical practice
recommendations. It can also provide transparency for
consumers by fixing pricing and by publishing cost and
outcomes data. Some European countries have intro-
duced episode-based payment: Portugal did so in 2008
for dialysis, and the Netherlands did so in 2010 for type
two diabetes, chronic obstructive pulmonary disease
(COPD) and vascular risk management [20, 21]. In
France, several ongoing pilot studies are focusing on
bundled payment for outpatient surgery [22], chronic
renal insufficiency and radiation treatment for cancer.
The assessment of care pathways encourages the im-
plementation of new payment models. Our approach
could help health care professionals and policy makers
establish other cost-of-illness studies and plan resource
allocation on a patient basis rather than on a visit basis.
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